Close Menu

Lung Cancer

News and reporting on lung cancer.

DNA mutations and microRNA profiles of lung cancer tumors differ between patients who have smoked compared with those who haven't, a National Cancer Institute researcher reported at AACR.

The firm reported no revenues, but it managed to cut its net loss as it prepares to launch its LungExpress Dx product in the US later this year.

The companies — Rosetta Genomics, MDRNA, and Tekmira Pharmaceuticals — have all seen their shares more than double since Dec. 31, significantly outperforming the Nasdaq Biotechnology Index.

A separate deal under which Prometheus agreed to acquire 2 million shares of Rosetta at $4 per share has also been completed.

NCI Director John Niederhuber said last week that the institute plans to expand the Cancer Genome Atlas project to 20 to 25 major tumor types, and to apply next-generation sequencing to at least 100 tumor samples for each of several types of childhood cancers under the TARGET initiative.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Based on the results of the study, the company has assembled a panel of six protein biomarkers with the ability to detect non-small cell lung cancer in patients with 94 percent sensitivity and 93 percent specificity. The company is hoping to launch the test by 2012.

Attendees heard about the past and future of the Cancer Genome Atlas at the American Association for Cancer Research meeting in Denver this week, as the pilot stage of the project nears completion.

In doing so, Rosetta is meeting its objective of finding commercialization partners for its existing products as it shifts its focus onto tests that screen for, rather than diagnose, disease.

Personalized medicine

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.